Aclaris Therapeutics (ACRS) Operating Margin (2017 - 2025)
Historic Operating Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 519.82%.
- Aclaris Therapeutics' Operating Margin fell 2788900.0% to 519.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 973.93%, marking a year-over-year decrease of 8029400.0%. This contributed to the annual value of 758.18% for FY2024, which is 4466300.0% down from last year.
- As of Q3 2025, Aclaris Therapeutics' Operating Margin stood at 519.82%, which was down 2788900.0% from 1035.9% recorded in Q2 2025.
- Aclaris Therapeutics' 5-year Operating Margin high stood at 23.03% for Q4 2023, and its period low was 1702.25% during Q2 2023.
- Over the past 5 years, Aclaris Therapeutics' median Operating Margin value was 1035.9% (recorded in 2025), while the average stood at 901.37%.
- Examining YoY changes over the last 5 years, Aclaris Therapeutics' Operating Margin showed a top increase of 12375300bps in 2024 and a maximum decrease of -10591000bps in 2024.
- Over the past 5 years, Aclaris Therapeutics' Operating Margin (Quarter) stood at 1525.18% in 2021, then skyrocketed by 75bps to 375.07% in 2022, then skyrocketed by 94bps to 23.03% in 2023, then tumbled by -4598bps to 1082.13% in 2024, then soared by 52bps to 519.82% in 2025.
- Its Operating Margin was 519.82% in Q3 2025, compared to 1035.9% in Q2 2025 and 1242.89% in Q1 2025.